ArticleThe Journal of antimicrobial chemotherapy2026
National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
backgroundHIV pretreatment drug resistance (PDR) is an increasing global concern affecting transmitted resistance and first-line therapy effectiveness. Colombia lacks recent nationwide data on transmitted resistance. Although national guidelines recommend second-generation integrase strand transfer inhibitors (INSTIs) as preferred first-line options, efavirenz remains widely prescribed. This study estimated HIV PDR prevalence in Colombia to inform best practices for first-line antiretroviral therapy.
methodsWe conducted a cross-sectional, nationally representative survey using next-generation sequencing of plasma samples from individuals initiating or reinitiating first-line antiretroviral treatment across Colombia's natural regions, stratified by national HIV prevalence data. Samples collected between 2021 and 2023 were analysed for drug resistance mutations (DRMs) following World Health Organization recommendations and interpreted using Stanford HIVdb v9.6.
resultsA total of 483 participants were enrolled; 98.3% had HIV-1 subtype B, 94.3% were Colombian nationals, the median age was 32.5 years (standard deviation ± 10.8), 19.9% were female, and 27.5% had CD4 counts <200 cells/mm³. Median HIV-1 RNA was 54 754 copies/mL (interquartile range [IQR]: 15 685-166 000); 6.2% were treatment reinitiators. The wild-type virus was identified in 61.7%. Overall, PDR prevalence was 20.3% (95% confidence interval [CI] 16.8-24.2), driven mainly by non-nucleoside reverse transcriptase inhibitor resistance (NNRTI) (18.0%, 95% CI 14.7-21.7), with K103N as the most frequent DRM. INSTI DRMs were rare (2.1%).
conclusionsThis nationwide survey demonstrates alarmingly high NNRTI resistance but minimal INSTI resistance, underscoring the urgent need to phase out efavirenz-based regimens. Strengthening access to affordable second-generation-based therapies and enhancing prescriber education are critical to sustaining treatment efficacy and preventing further transmission of resistant HIV strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.